Island Pharmaceuticals has secured a critical collaboration with Texas Biomedical Research Institute to advance dose optimisation for its antiviral Galidesivir, targeting Marburg Virus Disease under the FDA Animal Rule. This second phase complements ongoing USAMRIID efforts and aims to de-risk pivotal study design with data from 32 non-human primates.
- Texas Biomed to evaluate Galidesivir at symptom onset in 12 primates
- Study uses FDA-preferred Angola strain for regulatory alignment
- Complements USAMRIID’s early treatment dose optimisation
- Secures additional animal cohorts for operational flexibility
- Supports pivotal Animal Rule study design and regulatory package
Strategic Collaboration Targets Critical Dose Optimisation
Island Pharmaceuticals Ltd (ASX:ILA) has taken a significant step towards pivotal development of its broad-spectrum antiviral Galidesivir by executing a Statement of Work with Texas Biomedical Research Institute (Texas Biomed). This agreement expands the dose optimisation program essential for the planned FDA Animal Rule efficacy study against Marburg Virus Disease, a high-priority biodefence threat with no approved treatments.
Texas Biomed, a leading US-based non-profit infectious disease institute and one of only four BSL-4 facilities capable of conducting non-human primate (NHP) studies with Marburg virus, will evaluate Galidesivir in 12 NHPs infected with the FDA-preferred Angola strain. The study focuses on treatment initiation correlating with the onset of clinical signs, typically 3 to 5 days post-infection, complementing the ongoing USAMRIID program that assesses dosing within 24 to 48 hours of infection.
Dual Studies to De-Risk Pivotal Trial Design
The combined USAMRIID and Texas Biomed studies will generate comprehensive pharmacokinetic, efficacy, and treatment timing data across multiple windows, crucial for identifying the minimally effective dose and optimising pivotal study parameters. By securing access to a second cohort of animals through Texas Biomed, Island mitigates risks associated with NHP availability; a significant bottleneck in biodefence research; and gains operational flexibility to maintain development momentum.
Animal preparation activities at Texas Biomed are slated to begin in the fourth quarter of 2026, with infection and treatment phases scheduled for early 2027. This timeline aligns with ongoing USAMRIID efforts, ensuring continuous progress towards the pivotal Animal Rule study.
Biodefence Positioning and Regulatory Alignment
Texas Biomed’s involvement bolsters Island’s credibility within the US biodefence ecosystem, reinforcing its position as a serious contender for government partnerships. The FDA has provided clear guidance on Galidesivir’s regulatory pathway under the Animal Rule, recommending completion of dose optimisation studies prior to finalising pivotal study design. This dual-site approach addresses that directive, enhancing the scientific and regulatory foundation ahead of pivotal development.
Island’s CEO, Dr David Foster, emphasised the importance of this disciplined approach in targeting an unmet medical need with significant national security implications. The program’s success could unlock eligibility for a Priority Review Voucher valued at approximately US$200 million and pave the way for Strategic National Stockpile procurement and international government contracts.
Next Steps and Milestones to Watch
Investors should monitor the commencement of USAMRIID Cohort 1 dosing, survival results from that study, the initiation of Texas Biomed’s animal preparation, and forthcoming pharmacokinetic and survival readouts. Finalisation of the pivotal study design and updates on Priority Review Voucher status and government procurement discussions will be critical milestones as Island advances Galidesivir towards regulatory approval under the Animal Rule.
Bottom Line?
Island’s partnership with Texas Biomed adds vital depth to Galidesivir’s dose optimisation, positioning the antiviral for a robust pivotal study and potential biodefence procurement.
Questions in the middle?
- Will the dual-site dose optimisation strategy sufficiently address FDA expectations for pivotal study design?
- How might operational flexibility from additional animal cohorts influence timelines amid NHP scarcity?
- What impact could successful Animal Rule approval have on Island’s commercial and biodefence partnerships?